![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
PILOT
831175
XINGANJIANG
873167
Beijing Highlander Digital Technology
300065
4
Hangzhou Gaoxin Materials Technology
300478
5
Shijihengtong Technology
301428
US Stock MarketDetailed Quotes
CTXR Citius Pharmaceuticals
- 2.6900
- -0.0100-0.37%
Close Feb 14 16:00 ET
- 2.5500
- -0.1400-5.20%
Post 17:26 ET
23.12MMarket Cap-0.46P/E (TTM)
2.8194High2.6400Low98.49KVolume2.7100Open2.7000Pre Close267.09KTurnover1.41%Turnover RatioLossP/E (Static)8.59MShares26.750052wk High0.35P/B18.76MFloat Cap2.440052wk Low--Dividend TTM6.97MShs Float750.0000Historical High--Div YieldTTM6.64%Amplitude2.4400Historical Low2.7110Avg Price1Lot Size
Citius Pharmaceuticals Stock Forum
Sign in to post a comment
$Citius Pharmaceuticals (CTXR.US)$
Citius Pharmaceuticals Secures Critical J-Code for LYMPHIR as Cash Reserves Hit $1.1M
Citius Pharmaceuticals Secures Critical J-Code for LYMPHIR as Cash Reserves Hit $1.1M
1
2
$Citius Pharmaceuticals (CTXR.US)$
Medicare Breakthrough: Citius's Cancer Drug LYMPHIR Gets Crucial Insurance Code - Major Win for CTCL Patients
Medicare Breakthrough: Citius's Cancer Drug LYMPHIR Gets Crucial Insurance Code - Major Win for CTCL Patients
1
$Citius Pharmaceuticals (CTXR.US)$ $Citius Oncology (CTOR.US)$ Reuters· just
Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for Lymphir by Centers for Medicare and Medicaid Services
Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for Lymphir by Centers for Medicare and Medicaid Services
5
$Citius Pharmaceuticals (CTXR.US)$
Citius Pharmaceuticals Advances LYMPHIR Launch Plans for Breakthrough CTCL Treatment
Citius Pharmaceuticals Advances LYMPHIR Launch Plans for Breakthrough CTCL Treatment
3
$Citius Pharmaceuticals (CTXR.US)$ $Citius Oncology (CTOR.US)$ Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025
PR Newswire· 4 mins ago
PR Newswire· 4 mins ago
2
$Citius Pharmaceuticals (CTXR.US)$ $Citius Oncology (CTOR.US)$
Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025
Tuesday, 7th January at 8:08 am
CRANFORD, N.J., Jan. 7, 2025 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (NASDAQ: CTXR) and its oncology-focused subsidiary, Citius Oncology (NASDAQ: CTOR), today announced significant progress in preparations for the commercial launch of LYMPHIR™, an i...
Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025
Tuesday, 7th January at 8:08 am
CRANFORD, N.J., Jan. 7, 2025 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (NASDAQ: CTXR) and its oncology-focused subsidiary, Citius Oncology (NASDAQ: CTOR), today announced significant progress in preparations for the commercial launch of LYMPHIR™, an i...
$Citius Pharmaceuticals (CTXR.US)$
The engagement of Jefferies as a financial advisor is a strategically significant move that could reshape Citius Oncology's future. Jefferies' strong track record in healthcare M&A and their expertise in orchestrating deals averaging $500M-$2B in the biotech sector positions them well to explore value-maximizing opportunities. With LYMPHIR™ recently FDA-approved and ready for commercialization, the timing aligns perfectly with...
The engagement of Jefferies as a financial advisor is a strategically significant move that could reshape Citius Oncology's future. Jefferies' strong track record in healthcare M&A and their expertise in orchestrating deals averaging $500M-$2B in the biotech sector positions them well to explore value-maximizing opportunities. With LYMPHIR™ recently FDA-approved and ready for commercialization, the timing aligns perfectly with...
6
$Citius Pharmaceuticals (CTXR.US)$
Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives
Monday, 6th January at 7:50 am
CRANFORD, N.J., Jan. 6, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or "the Company") (NASDAQ: CTOR), a majority-owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (NASDAQ: CTXR), today announced that it has retained Jefferies LLC as its exclusive financial advisor to assist in evaluating strategi...
Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives
Monday, 6th January at 7:50 am
CRANFORD, N.J., Jan. 6, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or "the Company") (NASDAQ: CTOR), a majority-owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (NASDAQ: CTXR), today announced that it has retained Jefferies LLC as its exclusive financial advisor to assist in evaluating strategi...
18
11
No comment yet
Trending Stocks
Discussing
Major earnings are approaching! What's ahead for Chinese stocks in 2025?
Recently, institutions such as Goldman Sachs, Morgan Stanley, and Appaloosa LP have spoken positively about Chinese assets. 🎙️Discussion: 1
Popular on moomoo
Feb 13 17:34
China's asset revaluation sparks debate: What are mooers buying?
萬軍無兵策天鳳 : Summary: There is no hope left.![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")
71079745 萬軍無兵策天鳳 : There is hope, there is hope, do not be too pessimistic, we simply won't buy it.